Takuya Haraguchi

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 112 citations · Full text

Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in <scp>J</scp> apanese individuals with type 2 diabetes: <scp>A</scp> randomized, open‐label, 3‐arm parallel comparative, exploratory study

Daisuke Yabe, Masahiro Iwasaki, Hitoshi Kuwata et al. · Diabetes Obesity and Metabolism · 2016 · 67 citations · Full text

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

Hitoshi Kuwata, Daisuke Yabe, Kenta Murotani et al. · Journal of Diabetes Investigation · 2021 · 38 citations · Full text

Lifestyle changes as a result of COVID‐19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency

Nagaaki Tanaka, Yoshiyuki Hamamoto, Yuri Kurotobi et al. · Journal of Diabetes Investigation · 2021 · 37 citations · Full text

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 32 citations · Full text